Cipla
Search results
Download annual reports of Sun Pharma from 1999 to 2023, including financial results, corporate governance, and sustainability. See the latest report for 2022-2023 and the managing director's message.
- Scaling up Specialty. Leading with Care.
As per SMSRC data for February 2022, Sun Pharma ranks No. 1...
- CONTINUOUS
Our Annual Report cover is a creative representation. Sun...
- Scaling up Specialty. Leading with Care.
As per SMSRC data for February 2022, Sun Pharma ranks No. 1 by prescriptions with 11 different classes of doctors. We continued our new launches momentum with 77 new
Our Annual Report cover is a creative representation. Sun Pharma strictly follows all Covid-19 protocols and strongly recommends that everyone wears a mask during the pandemic.
- 7MB
- 296
Sun Pharma holds 8.3% market share and is ranked No. 1 in the Rs. 1,850 Billion plus Indian pharmaceutical market as per AIOCD AWACS MAT March-2023 report. For Q4FY23, the company launched 24 new products in the
Annual Report 2018-19 1 SPECIALTY IN PROGRESS We, at Sun Pharma, view our specialty business as an additional engine of sustainable growth and cashflows over the long term. The specialty business also represents our important initiative to move up the pharmaceutical value chain and usher in enhanced innovation for our business. Over the
Sun Pharmaceutical Industries Ltd. Annual Reports: Review of financial performance, strategy, and achievements.
People also ask
What is Sun Pharma's annual report cover?
What is the market share of Sun Pharma in India?
Where can I find information about Sun Pharma shareholders?
Where can I find the Sun Pharma sustainability report?
Highlights of Q1FY22 consolidated financials. Consolidated sales from operations at Rs. 96,694 million, growth of 29% over Q1 last year and 14% over Q4 last year. India sales at Rs. 33,084 million, up 39% compared to Q1 last year. US finished dosage sales at US$ 380 million, growth of 35% over same quarter last year.
